ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS) released its second-quarter financial results for the period ended June 30, 2026, demonstrating net sales of $185.6 million, an increase of 50 percent year over year on a reported basis and 49 percent year over year on a constant-currency basis. Of that, glaucoma net sales totaled $155.2 million, also up 50 percent year over year, while glaucoma net sales in the U.S. reached $118.5 million during the quarter, representing 64 percent year-over-year growth. An ophthalmic pharmaceutical and med-tech company, Glaukos is focused on novel therapies that treat glaucoma, corneal disorders and retinal diseases.
“Our record second quarter results reflect successful global execution across our key commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, chairman and CEO of Glaukos. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Gross margin for the second quarter of 2026 was approximately 82 percent, while non-GAAP gross margin for the quarter was approximately 85 percent, the company reported. Selling, general and administrative (SG&A) expenses for the second quarter of 2026 increased 39 percent to $116.1 million, compared with $83.4 million in the second quarter of 2025, while non-GAAP SG&A expenses increased 34 percent to $111.7 million, compared with $83.1 million in the prior-year period.
GAAP and non-GAAP research and development expenses for the second quarter of 2026 increased 40 percent to $51.3 million, compared with $36.5 million in the second quarter of 2025, the company reported. Loss from operations was $17.3 million, compared with an operating loss of $22.7 million in the same period last year, while non-GAAP loss from operations was $7.6 million, compared with a non-GAAP operating loss of $16.6 million in the prior-year’s quarter.
Net loss in the second quarter of 2026 was $18.4 million, compared with a net loss of $19.7 million in the same period last year, the company said. Non-GAAP net loss was $8.3 million compared with a non-GAAP net loss of $13.6 million versus Q2 of 2025.
Glaukos said it ended the second quarter of 2026 with approximately $289.3 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt. The company now expects 2026 net sales to range from $680 million to $700 million based on current foreign exchange rates, as compared with the previously expected $620 million to $635 million.
